Journal of Clinical Endocrinology & Metabolism, Vol 80, 153-159, Copyright © 1995 by Endocrine Society

ARTICLES

The effect of low dose recombinant human growth hormone replacement on regional fat distribution, insulin sensitivity, and cardiovascular risk factors in hypopituitary adults

JU Weaver, JP Monson, K Noonan, WG John, A Edwards, KA Evans and J Cunningham
Department of Endocrinology, Royal London Hospital and Medical College, United Kingdom.

GH deficiency is associated with increased cardiovascular morbidity, which may be determined by alterations in vascular risk factors. We report the effect of partially treated hypopituitarism and subsequent GH replacement (mean dose, 0.2 IU/kg.week) on putative cardiovascular risk factors in 22 nondiabetic hypopituitary subjects in a 6-month, double blind, controlled study (active/placebo ratio, 11:11). All patients were subsequently treated with GH for a further 6 months. Total fat, percent body fat, and central fat were measured by dual energy x-ray absorptiometry. The hypopituitary patients had increased percent fat (P = 0.03) and central fat (P < 0.01) compared with body mass index-matched controls. Before GH treatment, fasting (total) and specific insulin positively correlated with body mass index (P = 0.02 and P < 0.001, respectively), waist/hip ratio (P = 0.05 and P = 0.01), and central fat (P = 0.03 and P = 0.003). Specific insulin and insulin sensitivity (IS), calculated by homeostatic model of assessment, were related to total fat (P < 0.001 and P = 0.02). GH treatment for 6 months led to a reduction in total fat (P < 0.02), percent fat (P = 0.002), central fat (P = 0.012), waist/hip ratio (P < 0.05), total cholesterol (P = 0.03), and apolipoprotein-B (P = 00001), as well as a decrease in the IS from 36.9% (range, 12-100%) to 25% (range, 2.5-55%; P = 0.0002). This was paralleled by a rise in fasting (total) and specific insulin (P = 0.016 and P = 0.002). The degree of correlation among indices of IS, body composition, and fat distribution increased after GH treatment. Fasting plasma glucose rose significantly, but was within the reference range. During 12 months of GH therapy, a significant increase in serum lipoprotein-(a) was observed (P < 0.05). Although GH has beneficial effects on central adiposity and lipid fractions, it is also associated with a decrease in IS; these effects may vary between individuals.

This article has been cited by other articles:

				C. Beauregard, A. L. Utz, A. E. Schaub, L. Nachtigall, B. M. K. Biller, K. K. Miller, and A. Klibanski Growth Hormone Decreases Visceral Fat and Improves Cardiovascular Risk Markers in Women with Hypopituitarism: A Randomized, Placebo-Controlled Study J. Clin. Endocrinol. Metab., June 1, 2008; 93(6): 2063 - 2071. [Abstract] [Full Text] [PDF]

				J. K. Devin, L. S. Blevins Jr., D. K. Verity, Q. Chen, J. R. Bloodworth Jr., J. Covington, and D. E. Vaughan Markedly Impaired Fibrinolytic Balance Contributes to Cardiovascular Risk in Adults with Growth Hormone Deficiency J. Clin. Endocrinol. Metab., September 1, 2007; 92(9): 3633 - 3639. [Abstract] [Full Text] [PDF]

				R. Abs, U. Feldt-Rasmussen, A. F Mattsson, J. P Monson, B.-A. Bengtsson, M. I Goth, P. Wilton, and M. Koltowska-Haggstrom Determinants of cardiovascular risk in 2589 hypopituitary GH-deficient adults - a KIMS database analysis. Eur. J. Endocrinol., July 1, 2006; 155(1): 79 - 90. [Abstract] [Full Text] [PDF]

				L. J. Woodhouse, A. Mukherjee, S. M. Shalet, and S. Ezzat The Influence of Growth Hormone Status on Physical Impairments, Functional Limitations, and Health-Related Quality of Life in Adults Endocr. Rev., May 1, 2006; 27(3): 287 - 317. [Abstract] [Full Text] [PDF]

				M. E. Molitch, D. R. Clemmons, S. Malozowski, G. R. Merriam, S. M. Shalet, M. L. Vance, and for The Endocrine Society's Clinical Guidelines Su Evaluation and Treatment of Adult Growth Hormone Deficiency: An Endocrine Society Clinical Practice Guideline J. Clin. Endocrinol. Metab., May 1, 2006; 91(5): 1621 - 1634. [Abstract] [Full Text] [PDF]

				J. Svensson, H. Herlitz, P.-A. Lundberg, and G. Johannsson Adiponectin, Leptin, and Erythrocyte Sodium/Lithium Countertransport Activity, But Not Resistin, Are Related to Glucose Metabolism in Growth Hormone-Deficient Adults J. Clin. Endocrinol. Metab., April 1, 2005; 90(4): 2290 - 2296. [Abstract] [Full Text] [PDF]

				M. Gola, S. Bonadonna, M. Doga, and A. Giustina Growth Hormone and Cardiovascular Risk Factors J. Clin. Endocrinol. Metab., March 1, 2005; 90(3): 1864 - 1870. [Abstract] [Full Text] [PDF]

				K. K. Miller, B. M. K. Biller, J. G. Lipman, G. Bradwin, N. Rifai, and A. Klibanski Truncal Adiposity, Relative Growth Hormone Deficiency, and Cardiovascular Risk J. Clin. Endocrinol. Metab., February 1, 2005; 90(2): 768 - 774. [Abstract] [Full Text] [PDF]

				O. Serri, L. Li, F. Maingrette, N. Jaffry, and G. Renier Enhanced Lipoprotein Lipase Secretion and Foam Cell Formation by Macrophages of Patients with Growth Hormone Deficiency: Possible Contribution to Increased Risk of Atherogenesis? J. Clin. Endocrinol. Metab., February 1, 2004; 89(2): 979 - 985. [Abstract] [Full Text] [PDF]

				J. W. Tomlinson, N. Crabtree, P. M. S. Clark, G. Holder, A. A. Toogood, C. H. L. Shackleton, and P. M. Stewart Low-Dose Growth Hormone Inhibits 11{beta}-Hydroxysteroid Dehydrogenase Type 1 but Has No Effect upon Fat Mass in Patients with Simple Obesity J. Clin. Endocrinol. Metab., May 1, 2003; 88(5): 2113 - 2118. [Abstract] [Full Text] [PDF]

				J. Svensson and B.-A. Bengtsson Growth Hormone Replacement Therapy and Insulin Sensitivity J. Clin. Endocrinol. Metab., April 1, 2003; 88(4): 1453 - 1454. [Full Text] [PDF]

				M. Bramnert, M. Segerlantz, E. Laurila, J. R. Daugaard, P. Manhem, and L. Groop Growth Hormone Replacement Therapy Induces Insulin Resistance by Activating the Glucose-Fatty Acid Cycle J. Clin. Endocrinol. Metab., April 1, 2003; 88(4): 1455 - 1463. [Abstract] [Full Text] [PDF]

				Why start an adult on growth hormone? DTB, October 1, 2002; 40(10): 75 - 78. [Abstract] [Full Text] [PDF]

				W. L. Isley Growth Hormone Therapy for Adults: Not Ready for Prime Time? Ann Intern Med, August 6, 2002; 137(3): 190 - 196. [Abstract] [Full Text] [PDF]

				J. A. S. Barreto-Filho, M. R. S. Alcantara, R. Salvatori, M. A. Barreto, A. C. S. Sousa, V. Bastos, A. H. Souza, R. M. C. Pereira, P. E. Clayton, M. S. Gill, et al. Familial Isolated Growth Hormone Deficiency Is Associated with Increased Systolic Blood Pressure, Central Obesity, and Dyslipidemia J. Clin. Endocrinol. Metab., May 1, 2002; 87(5): 2018 - 2023. [Abstract] [Full Text] [PDF]

				S. Porretti, C. Giavoli, C. Ronchi, G. Lombardi, M. Zaccaria, D. Valle, M. Arosio, and P. Beck-Peccoz Recombinant Human GH Replacement Therapy and Thyroid Function in a Large Group of Adult GH-Deficient Patients: When Does L-T4 Therapy Become Mandatory? J. Clin. Endocrinol. Metab., May 1, 2002; 87(5): 2042 - 2045. [Abstract] [Full Text] [PDF]

				J. Svensson, J. Fowelin, K. Landin, B.-A. Bengtsson, and J.-O. Johansson Effects of Seven Years of GH-Replacement Therapy on Insulin Sensitivity in GH-Deficient Adults J. Clin. Endocrinol. Metab., May 1, 2002; 87(5): 2121 - 2127. [Abstract] [Full Text] [PDF]

				R. D. Murray, K. H. Darzy, H. K. Gleeson, and S. M. Shalet GH-Deficient Survivors of Childhood Cancer: GH Replacement during Adult Life J. Clin. Endocrinol. Metab., January 1, 2002; 87(1): 129 - 135. [Abstract] [Full Text] [PDF]

				G. Sesmilo, K. K. Miller, D. Hayden, and A. Klibanski Inflammatory Cardiovascular Risk Markers in Women with Hypopituitarism J. Clin. Endocrinol. Metab., December 1, 2001; 86(12): 5774 - 5781. [Abstract] [Full Text] [PDF]

				M. Segerlantz, M. Bramnert, P. Manhem, E. Laurila, and L. C. Groop Inhibition of the Rise in FFA by Acipimox Partially Prevents GH-Induced Insulin Resistance in GH-Deficient Adults J. Clin. Endocrinol. Metab., December 1, 2001; 86(12): 5813 - 5818. [Abstract] [Full Text] [PDF]

				G. Frajese, W. M. Drake, R. A. Loureiro, J. Evanson, D. Coyte, D. F. Wood, A. B. Grossman, G. M. Besser, and J. P. Monson Hypothalamo-Pituitary Surveillance Imaging in Hypopituitary Patients Receiving Long-Term GH Replacement Therapy J. Clin. Endocrinol. Metab., November 1, 2001; 86(11): 5172 - 5175. [Abstract] [Full Text] [PDF]

				E. Hernberg-Stahl, A. Luger, R. Abs, B.-A. Bengtsson, U. Feldt-Rasmussen, P. Wilton, B. Westberg, and J. P. Monson Healthcare Consumption Decreases in Parallel with Improvements in Quality of Life during GH Replacement in Hypopituitary Adults with GH Deficiency J. Clin. Endocrinol. Metab., November 1, 2001; 86(11): 5277 - 5281. [Abstract] [Full Text] [PDF]

				E. M. McConnell, A. B. Atkinson, C. Ennis, D. R. Hadden, D. R. McCance, B. Sheridan, and P. M. Bell The Effects on Insulin Action in Adult Hypopituitarism of Recombinant Human GH Therapy Individually Titrated for Six Months J. Clin. Endocrinol. Metab., November 1, 2001; 86(11): 5342 - 5347. [Abstract] [Full Text] [PDF]

				H. Pijl, J. G. Langendonk, J. Burggraaf, M. Frolich, A. F. Cohen, J. D. Veldhuis, and A. E. Meinders Altered Neuroregulation of GH Secretion in Viscerally Obese Premenopausal Women J. Clin. Endocrinol. Metab., November 1, 2001; 86(11): 5509 - 5515. [Abstract] [Full Text] [PDF]

				W. M. Drake, S. J. Howell, J. P. Monson, and S. M. Shalet Optimizing GH Therapy in Adults and Children Endocr. Rev., August 1, 2001; 22(4): 425 - 450. [Abstract] [Full Text] [PDF]

				G. Sesmilo, B. M. K. Biller, J. Llevadot, D. Hayden, G. Hanson, N. Rifai, and A. Klibanski Effects of Growth Hormone (GH) Administration on Homocyst(e)ine Levels in Men with GH Deficiency: A Randomized Controlled Trial J. Clin. Endocrinol. Metab., April 1, 2001; 86(4): 1518 - 1524. [Abstract] [Full Text]

				A. M. Rosenfalck, S. Maghsoudi, S. Fisker, J. O. L. Jørgensen, J. S. Christiansen, J. Hilsted, A. Vølund, and S. Madsbad The Effect of 30 Months of Low-Dose Replacement Therapy with Recombinant Human Growth Hormone (rhGH) on Insulin and C-Peptide Kinetics, Insulin Secretion, Insulin Sensitivity, Glucose Effectiveness, and Body Composition in GH-Deficient Adults J. Clin. Endocrinol. Metab., November 1, 2000; 85(11): 4173 - 4181. [Abstract] [Full Text]

				G. Sesmilo, B. M.K. Biller, J. Llevadot, D. Hayden, G. Hanson, N. Rifai, and A. Klibanski Effects of Growth Hormone Administration on Inflammatory and Other Cardiovascular Risk Markers in Men with Growth Hormone Deficiency: A Randomized, Controlled Clinical Trial Ann Intern Med, July 18, 2000; 133(2): 111 - 122. [Abstract] [Full Text] [PDF]

				J. A. M. Beentjes, A. van Tol, W. J. Sluiter, and R. P. F. Dullaart Effect of growth hormone replacement therapy on plasma lecithin:cholesterol acyltransferase and lipid transfer protein activities in growth hormone-deficient adults J. Lipid Res., June 1, 2000; 41(6): 925 - 932. [Abstract] [Full Text]

				B. Bülow, L. Hagmar, J. Eskilsson, and E. M. Erfurth Hypopituitary Females Have a High Incidence of Cardiovascular Morbidity and an Increased Prevalence of Cardiovascular Risk Factors J. Clin. Endocrinol. Metab., February 1, 2000; 85(2): 574 - 584. [Abstract] [Full Text]

				J. Svensson, J.-O. Jansson, M. Ottosson, G. Johannsson, M.-R. Taskinen, O. Wiklund, and B.-A. Bengtsson Treatment of Obese Subjects with the Oral Growth Hormone Secretagogue MK-677 Affects Serum Concentrations of Several Lipoproteins, But Not Lipoprotein(a) J. Clin. Endocrinol. Metab., June 1, 1999; 84(6): 2028 - 2033. [Abstract] [Full Text]

				K. A. Robinson, S. M. Willi, S. Bingel, and M. G. Buse Decreased hexosamine biosynthesis in GH-deficient dwarf rat muscle. Reversal with GH, but not IGF-I, therapy Am J Physiol Endocrinol Metab, March 1, 1999; 276(3): E435 - E442. [Abstract] [Full Text] [PDF]

				O. Serri, P. St-Jacques, M. Sartippour, and G. Renier Alterations of Monocyte Function in Patients with Growth Hormone (GH) Deficiency: Effect of Substitutive GH Therapy J. Clin. Endocrinol. Metab., January 1, 1999; 84(1): 58 - 63. [Abstract] [Full Text]

				W. M. Drake, D. Coyte, C. Camacho-Hübner, N. M. Jivanji, G. Kaltsas, D. F. Wood, P. J. Trainer, A. B. Grossman, G. M. Besser, and J. P. Monson Optimizing Growth Hormone Replacement Therapy by Dose Titration in Hypopituitary Adults J. Clin. Endocrinol. Metab., November 1, 1998; 83(11): 3913 - 3919. [Abstract] [Full Text]

				M. Christopher, F. L. Hew, M. Oakley, C. Rantzau, and F. Alford Defects of Insulin Action and Skeletal Muscle Glucose Metabolism in Growth Hormone-Deficient Adults Persist after 24 Months of Recombinant Human Growth Hormone Therapy J. Clin. Endocrinol. Metab., May 1, 1998; 83(5): 1668 - 1681. [Abstract] [Full Text]

				P. V. Carroll, E. R. Christ the members of Growth Hormone Research Soci, B. A. Bengtsson, L. Carlsson, J. S. Christiansen, D. Clemmons, R. Hintz, K. Ho, Z. Laron, P. Sizonenko, et al. Growth Hormone Deficiency in Adulthood and the Effects of Growth Hormone Replacement: A Review J. Clin. Endocrinol. Metab., February 1, 1998; 83(2): 382 - 395. [Abstract] [Full Text]

				C.-M. Hwu, C. F. Kwok, T.-Y. Lai, K.-C. Shih, T.-S. Lee, L.-C. Hsiao, S.-H. Lee, V. S. Fang, and L.-T. Ho Growth Hormone (GH) Replacement Reduces Total Body Fat and Normalizes Insulin Sensitivity in GH-Deficient Adults: A Report of One-Year Clinical Experience J. Clin. Endocrinol. Metab., October 1, 1997; 82(10): 3285 - 3292. [Abstract] [Full Text] [PDF]

				P. D. K. Lee, S. K. Durham, V. Martinez, O. Vasconez, D. R. Powell, and J. Guevara-Aguirre Kinetics of Insulin-Like Growth Factor (IGF) and IGF-Binding Protein Responses to a Single Dose of Growth Hormone J. Clin. Endocrinol. Metab., July 1, 1997; 82(7): 2266 - 2274. [Abstract] [Full Text] [PDF]

				P. Burman, A. G. Johansson, A. Siegbahn, B. Vessby, and F. A. Karlsson Growth Hormone (GH)-Deficient Men Are More Responsive to GH Replacement Therapy Than Women J. Clin. Endocrinol. Metab., February 1, 1997; 82(2): 550 - 555. [Abstract] [Full Text] [PDF]